MEI Pharma, Inc.
13 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer (NCT05824559) | MEI Pharma, Inc. | 2023-08-07 |
| Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL (NCT05209308) | MEI Pharma, Inc. | 2022-11-22 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) (NCT04745832) | MEI Pharma, Inc. | 2021-08-13 |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) (NCT03768505) | MEI Pharma, Inc. | 2019-06-25 |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (NCT03547115) | MEI Pharma, Inc. | 2018-05-31 |
Track MEI Pharma, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.